文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Lp(a) lipoprotein redux--from curious molecule to causal risk factor.

作者信息

Kathiresan Sekar

出版信息

N Engl J Med. 2009 Dec 24;361(26):2573-4. doi: 10.1056/NEJMe0910792.

DOI:10.1056/NEJMe0910792
PMID:20032327
Abstract
摘要

相似文献

[1]
Lp(a) lipoprotein redux--from curious molecule to causal risk factor.

N Engl J Med. 2009-12-24

[2]
Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

N Engl J Med. 2009-12-24

[3]
Should we measure lipoprotein Lp(a)?

Arch Intern Med. 1997-6-9

[4]
[Apolipoprotein(a) phenotypes as markers of genetic susceptibility for cardiovascular risk in occupational medicine].

G Ital Med Lav Ergon. 1999

[5]
Low LPA gene kringle IV-2 repeat copy number association with elevated lipoprotein (a) concentration as an independent risk factor of coronary atherosclerotic heart disease in the Chinese Han population.

Lipids Health Dis. 2018-5-10

[6]
[Lipoprotein(a)--atherogenic waste product of evolution?].

Wien Med Wochenschr. 1994

[7]
Genetic variants in Lp(a) lipoprotein and coronary disease.

N Engl J Med. 2010-3-25

[8]
Drinking from the fire hose--statistical issues in genomewide association studies.

N Engl J Med. 2007-8-2

[9]
Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease.

Int J Mol Med. 2004-2

[10]
ApolipoproteinA1-75 G/A (M1-) polymorphism and lipoprotein(a); anti- vs. pro-Atherogenic properties.

Lipids Health Dis. 2007-8-6

引用本文的文献

[1]
The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis.

J Clin Med. 2019-6-10

[2]
Lipoprotein (a): Coming of Age at Last.

J Lipid Res. 2016-3

[3]
Targeting lipoprotein (a): an evolving therapeutic landscape.

Curr Atheroscler Rep. 2015-5

[4]
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution.

Nat Rev Cardiol. 2013-11

[5]
Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.

Drug Healthc Patient Saf. 2010

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索